Reasons for and time to discontinuation of rimonabant therapy: A modified prescription-event monitoring study

Drug Safety

Volumn 35, Issue 12, 2012, Pages 1147-1158

  Willemen, Marjolein J C ^a,b   Mantel Teeuwisse, Aukje K ^a,b   Buggy, Yvonne ^c,d   Layton, Deborah ^c,d   Straus, Sabine M J M ^b,e   Leufkens, Hubert G M ^a,b   Egberts, Toine C G ^a,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^d UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Prescription event monitoring; Psychiatric disorders; Rimonabant

Indexed keywords

RIMONABANT;

ADULT; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONVULSION; DEPRESSION; DESCRIPTIVE RESEARCH; DIARRHEA; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MENTAL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RANK SUM TEST; RISK BENEFIT ANALYSIS; SEIZURE;

ADULT; BODY MASS INDEX; CANNABINOID RECEPTOR ANTAGONISTS; COHORT STUDIES; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PIPERIDINES; PYRAZOLES; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84868611304     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11631330-000000000-00000     Document Type: Article

References (38)

1. Summary of product characteristics: Acomplia. Paris: Sanofi-Aventis, 2006 [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document- library/EPAR-Pro duct-Information/human/000666/WC500021287.pdf [Accessed 2010 Dec 20]
2. Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21.Neuropharmacology 2006; 51 (2): 358-66 (Pubitemid 44081792)
3. ParolaroD, Realini N, ViganoD, et al. The endocannabinoid system and psychiatric disorders. Exp Neurol 2010; 224 (1): 3-14
4. European Public Assessment Report (EPAR) for Acomplia-. Committee for Medicinal Products for Human Use (CHMP) [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm [Accessed 2010 Aug 03]
5. Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. JAMA 2008; 299 (13): 1601-2 (Pubitemid 351482800)
6. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Committee for Medicinal Products for Human Use [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ acomplia/53777708en.pdf [Accessed 2010 Aug 24]
7. Buggy Y, Cornelius V, Wilton L, et al. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34 (6): 501-9
8. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126 (2): 529-37
9. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299 (5): 532-9 (Pubitemid 351222546)
10. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86 (3): 202-10
11. Hugenholtz GW, Heerdink ER, Meijer WE, et al. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38 (3): 122-4 (Pubitemid 40965964)
12. Van Geffen EC, van der Wal SW, van Hulten R, et al. Evaluation of patients' experiences with antidepressants reported by means of a medicine reporting system. Eur J Clin Pharmacol 2007; 63 (12): 1193-9 (Pubitemid 350112763)
13. Breekveldt-Postma NS, Gerrits CM, Lammers JW, et al. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004; 98 (8): 752-9 (Pubitemid 38842778)
14. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90 (9): 1065-6 (Pubitemid 39127934)
15. Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23 (11): 2101-7 (Pubitemid 41830407)
16. Van Geffen EC, van Hulten R, Bouvy ML, et al. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008; 42 (2): 218-25 (Pubitemid 351238570)
17. BBC News. Weight loss pill warning issued, 19 July 2007 [online]. Available from URL: http://news.bbc.co.uk/2/hi/health/6907160.stm [Accessed 2012 Jan 10]
18. The Telegraph. Study links slimming drug to depression, 15 November 2007 [online]. Available from URL: http://www.telegraph.co.uk/news/uknews/1569548/ Study-linksslimming-drug-to-depression.html [Accessed 2012 Jan 10]
19. Daily Mail. Weight-loss pill taken by 40,000 'can lead to suicidal thoughts', 15 November 2007 [online]. Available from URL: http://www.dailymail. co.uk/health/article-494365/Weight-loss-pill-taken-40-000-lead-suicidal- thoughts. html [Accessed 2012 Jan 10]
20. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs. Pharmacoepidemiol Drug Saf 2009; 18 (7): 631-8
21. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Psychiatric and cardiovascular co-morbidities in patients with diabetes mellitus starting anti-obesity drug. Obesity (Silver Spring) 2008; 16 (10): 2331-5
22. Layton D, Hazell L, Shakir S. Modified prescription-event monitoring studies. Drug Saf 2011; 34 (12): e1-9
23. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31 (12): 2398-403
24. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30 (2): 255-64 (Pubitemid 38828533)
25. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 159 (10): 1653-64
26. Nose M, Barbui C, Gray R, et al. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183: 197-206 (Pubitemid 37070173)
27. Hazell L, Shaki SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-6
28. Acomplia: procedural steps taken and scientific information after authorisation [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Procedural-steps-taken-and-scientific-information-after- authorisation/human/000666/WC500021286.pdf [Accessed 2010 Dec 12]
29. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53 (21): 1925-32
30. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444 (7121): 840-6 (Pubitemid 46024990)
31. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132 (6): 2208-25 (Pubitemid 46693749)
32. Van Wijk BL, Klungel OH, Heerdink ER, et al. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005; 39 (2): 319-28 (Pubitemid 40165223)
33. Nietert PJ, Tilley BC, Zhao W, et al. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009; 47 (1): 32-40
34. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions, part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007; 41 (10): 1569-82 (Pubitemid 47479786)
35. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007; 41 (11): 1770-81 (Pubitemid 350044338)
36. Shakir S. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chichester: John Wiley & Sons Ltd, 2007: 307-16
37. McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ 1996; 313 (7059): 732-3
38. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study. BMJ 1998; 317 (7151): 119-20 (Pubitemid 28310619)